© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 17, 2014
Recent updates by the 8th Joint National Committee (JNC 8), the American and International Societies of Hypertension (ASH-ISH), and KDIGO recommend target blood pressure of less than 140/90 mm Hg for most individuals, including those with CKD.
Two major sets of hypertension guidelines released in 2014 contain more common threads than differences, and are intended to serve different purposes. Clinicians seeking guidance for managing hypertension in chronic kidney disease (CKD) can look for this common ground to avoid "guideline overload."
Guidelines for hypertension have converged on a blood pressure target of less than 140/90 mm Hg for most individuals with chronic kidney disease (CKD). However, studies still need to clarify optimal BPs for advanced disease and optimal cardiovascular prevention.
November 16, 2014
In the past there were few effective treatment options for serious conditions such as hepatitis C and lupus. However, recent scientific advances offer physicians and patients greatly improved options for effective management of these conditions, with fewer adverse events.
Though warfarin has long been the mainstay of anticoagulation in atrial fibrillation (AF), dosing is complicated by a host of factors, and the drug has a famously narrow therapeutic range. One way to fine-tune warfarin therapy is to account for genetic variation.
Obese patients present several challenges when it comes to gastric bypass, kidney transplant, and other surgeries. Several recent advances have reduced the risk of complications in this population.
November 15, 2014
Anticoagulation is recommended for members of the general population with atrial fibrillation, but its significant risks must be weighed carefully in the medically fragile chronic kidney disease population.
There are many factors to consider when treating patients who may be infected with the Ebola virus, including several that are unique to the virus and that had not been widely considered prior to the current outbreak.
Treatment of atrial fibrillation (AF) in patients with CKD may help prevent disease progression. Ablation has been shown produce marked improvement in kidney function as measured by eGFR. A prospective study of individuals undergoing catheter ablation for AF showed that most patients remained AF-free, and that eGFR improved significantly for those with persistent or longstanding persistent AF.
November 14, 2014
Secondary hyperparathyroidism can occur in CKD when the kidney loses its ability to produce active metabolites of vitamin D, and reduces phosphorus excretion. Cinacalcet seeks to interrupt the progression to severe unremitting hyperparathyroidism by mimicking calcium to the calcium-sensing receptors that control parathyroid hormone levels.
High Relapse Rate After Discontinuing Antiviral Therapy for HBV Patients With Cirrhosis
Insomnia, Hypersomnia Identified as Symptoms of Long COVID Syndrome
Study Evaluates Insomnia and Suicidality Among Healthcare Workers During COVID-19 Pandemic